Author + information
The aim of study. The study of the quality of life and clinical and laboratory indicators in patients with stable coronary heart disease (CHD) and in combination with diabetes mellitus type 2 (T2DM) and chronic obstructive pulmonary disease (COPD).
Included 67 patients of both sexes, aged 39-69 years. All patients were divided into 3 groups: patients with CHD (group I, n = 21, mean age 55.4 ± 6.8 years, male/female 16/5), with CHD and T2DM (group II, n = 21, mean age 58.8 ± 8.9 years, male/female 18/6), and CHD with COPD (group III, n = 22, mean age 59.2 ± 5.2 years, male/female 16/6). Clinical and anamnestic indices, heart rate at rest, ECG in 12 standard leads, blood pressure measurement, echocardiographic study, biochemical blood test, and quality of life of patients using the international questionnaire EQ-5D were evaluated.
In the CHD group with or without diabetes, the incidence of obesity is high, while in the COPD group, the mean BMI was below 29 kg/m2. According to the EQ-5 questionnaire, the decline in the quality of life of patients with CHD and diabetes was mainly due to such items as “discomfort”, “daily activities” and “anxiety/depression”. In patients with concomitant COPD, the maximum number of points was scored on the items responsible for “mobility”, “anxiety/depression”. In the absence of an explicit dilatation of the left ventricular cavity, relatively low values of the left ventricular ejection fraction relative to patients with isolated CHD were noted in group II and III patients. In patients with COPD and CHD, signs of an overload of the left atrium are revealed. Patients of group III were characterized by the presence of dopplerographic signs of pulmonary hypertension. The combination of CHD with diabetes and COPD was accompanied by an increase in plasma concentrations of urea, as well as more pronounced dyslipidemia.
Concomitant diabetes and COPD contribute to worsening of the patients with CHD, characterized by a decrease in the quality of life of patients, increased plasma concentrations of urea, as well as more pronounced dyslipidemia in CHD patients.